US-based VBI Vaccines sells manufacturing capabilities to China's Brii Biosciences for $33 M
US, Feb. 16 -- based VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, has announced agreements whereby China-based startup Brii Biosciences, subject to certain activities, is expected to acquire the intellectual property for VBI-2601, VBI's hepatitis B immunotherapeutic development programme, and eliminate payment obligations from the July 2023 agreements between VBI and Brii Bio; acquire manufacturing capabilities and certain related assets at VBI's Rehovot, Israel manufacturing facility, and enter into an exclusive license to develop and commercialise VBI-1901, VBI's glioblastoma (GBM) immunotherapeutic candidate, in the Asia Pacific region (APAC), exclud...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.